SCHEMBL3989080

SCHEMBL3989080

[CH2]C(=O)Nc1nncs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12467531 0.78 TAAR1 (0.57)
SCHEMBL16388044 0.77 HPGD (0.50)
SCHEMBL2872394 0.76 POLB (0.58)
SCHEMBL1970389 0.75 POLB (0.56)
SCHEMBL1107001 0.75 LMNA (0.62)
SCHEMBL8356392 0.75 POLB (0.56)
SCHEMBL12649504 0.75 POLB (0.60)
SCHEMBL9931372 0.73 POLB (0.55)
SCHEMBL19974323 0.72 NPC1 (0.58)
SCHEMBL19974322 0.72 NPC1 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102123763-A Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use thereof XENOPORT INC 2011-07-13 CN claimed
US-20090291921-A1 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-11-26 US claimed
WO-2009067541-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-05-28 WO claimed
US-20240240229-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT 2024-07-18 US disclosed
CN-115531366-A Method of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-30 CN disclosed
CN-115501218-A Methods of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-23 CN disclosed
CN-114146079-A Pharmaceutical composition containing dimethyl fumarate 比奥根玛公司 2022-03-08 CN disclosed
CN-114146081-A Pharmaceutical composition containing dimethyl fumarate 比奥根玛公司 2022-03-08 CN disclosed
CN-114146080-A Pharmaceutical composition containing dimethyl fumarate 比奥根玛公司 2022-03-08 CN disclosed
CN-113368093-A Methods of treating multiple sclerosis 比奥根玛公司 2021-09-10 CN disclosed
CN-113368091-A Methods of treating multiple sclerosis 比奥根玛公司 2021-09-10 CN disclosed
US-20070043069-A1 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans ASTRAZENECA AB (SE) 2007-02-22 US disclosed
US-7169927-B2 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2007-01-30 US disclosed
US-7129249-B2 Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase ASTRAZENECA AB (SE) 2006-10-31 US disclosed
US-20050131016-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-06-16 US disclosed
US-20050131015-A1 Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase ASTRAZENECA AB (SE) 2005-06-16 US disclosed
EP-1485371-A2 INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS AstraZeneca AB (SE) 2004-12-15 EP disclosed
EP-1483270-A1 HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE Astrazeneca AB (SE) 2004-12-08 EP disclosed
WO-2003074513-A2 INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2003-09-12 WO disclosed
WO-2003074532-A1 HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE ASTRAZENECA AB (SE) 2003-09-12 WO disclosed